D.E. Shaw & Co
FULC icon

D.E. Shaw & Co’s Fulcrum Therapeutics FULC Stock Holding History

D.E. Shaw & Co’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.1M Buy
3,044,385
+1,421,104
+88% +$8.64M 0.01% 1722
2026
Q1 		$12.5M Sell
1,623,281
-290,474
-15% -$2.69M 0.01% 1462
2025
Q4 		$21.6M Buy
1,913,755
+464,332
+32% +$4.73M 0.01% 1209
2025
Q3 		$13.3M Buy
1,449,423
+272,712
+23% +$1.97M 0.01% 1459
2025
Q2 		$8.1M Buy
1,176,711
+596,050
+103% +$3.19M 0.01% 1661
2025
Q1 		$1.67M Sell
580,661
-2,542
-0.4% -$9.34K ﹤0.01% 2735
2024
Q4 		$2.74M Sell
583,203
-174,528
-23% -$644K ﹤0.01% 2474
2024
Q3 		$2.71M Buy
757,731
+165,946
+28% +$1.23M ﹤0.01% 2458
2024
Q2 		$3.67M Sell
591,785
-33,391
-5% -$253K ﹤0.01% 2095
2024
Q1 		$5.9M Buy
625,176
+127,497
+26% +$1.14M 0.01% 1765
2023
Q4 		$3.36M Buy
497,679
+276,415
+125% +$1.23M ﹤0.01% 2250
2023
Q3 		$982K Buy
221,264
+75,042
+51% +$328K ﹤0.01% 3072
2023
Q2 		$483K Buy
146,222
+130,899
+854% +$385K ﹤0.01% 3438
2023
Q1 		$43.7K Sell
15,323
-160,823
-91% -$1.44M ﹤0.01% 4055
2022
Q4 		$1.28M Buy
176,146
+93,807
+114% +$612K ﹤0.01% 3273
2022
Q3 		$666K Sell
82,339
-57,143
-41% -$409K ﹤0.01% 3866
2022
Q2 		$683K Sell
139,482
-407,922
-75% -$3.99M ﹤0.01% 3882
2022
Q1 		$12.9M Sell
547,404
-304,744
-36% -$4.31M 0.01% 1369
2021
Q4 		$15.1M Buy
852,148
+54,047
+7% +$1.07M 0.01% 1301
2021
Q3 		$22.5M Buy
+798,101
New +$15.1M 0.02% 949

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

D.E. Shaw & Co's FULC Position: Q2 2026 in Review

D.E. Shaw & Co increased its Fulcrum Therapeutics (FULC) stake by 88% in Q2 2026, buying an estimated $8.64M and bringing the position to 3,044,385 shares worth $11.1M. The position accounts for 0.01% of the portfolio, ranked #1722.

D.E. Shaw & Co first reported a position in FULC in Q3 2021 and has held it in 20 quarters since. The position peaked at $22.5M in Q3 2021. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • D.E. Shaw & Co held 3,044,385 shares of Fulcrum Therapeutics worth $11.1M as of Q2 2026.
  • D.E. Shaw & Co bought 1,421,104 Fulcrum Therapeutics shares in Q2 2026, an estimated $8.64M.
  • Fulcrum Therapeutics made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1722 holding.
  • D.E. Shaw & Co first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • D.E. Shaw & Co's Fulcrum Therapeutics position peaked at $22.5M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.